In May this year consumer healthcare company Alliance Pharma (APH) faced audit-related results delay, its CEO leaving and was appealing a Competition and Markets Authority finding that it had infringed competition law and its fine. However, the subsequent half-year results suggest a much-improved picture but the shares have only currently recovered to a 46.8p offer price, which suggests to us significant further recovery potential.
This is, of course, a big fave of Nigel Wray and he has done exceptionally well from Alliance Pharma (APH). It has also been a good share tip (twice) from myself and young Steve on the Nifty Fifty. The main man is John Dawson and he can explain the story going forward.



